

October 09, 2025

Lupin Life Sciences Limited: Update on material event

Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating Outstanding
Short-term-fund-based/non-fund-based facilities	10.00	10.00	[ICRA]A1+
Unallocated limits	15.00	15.00	[ICRA]A1+
Total	25.00	25.00	

*Instrument details are provided in Annexure I

Rationale

While assigning the rating for Lupin Life Sciences Limited (LLSL), ICRA has taken a consolidated view of Lupin Limited (Lupin) and its wholly owned subsidiary, LLSL, given their common management and significant operational and financial linkages between them.

Material event

On September 29, 2025, Lupin announced the signing of a definitive agreement to acquire 100% equity in VISUfarma B.V. (VISUfarma), a speciality pharmaceutical company headquartered in Amsterdam, the Netherlands. VISUfarma focuses on ophthalmic products and has a strong commercial footprint across Italy, the UK, and Spain. In CY2024, the company reported revenues of EUR 48.1 million. The acquisition will be executed through Lupin's wholly owned subsidiary, Nanomi B.V., for a total consideration of EUR 190 million (approximately Rs. 2,000 crore). The transaction is expected to be completed by December 2025, subject to regulatory approvals in Germany and Spain.

Impact of material event

The acquisition will enable Lupin to broaden its European footprint beyond its current operations in the UK, Germany, and France, by entering relatively underpenetrated markets such as Italy and Spain while sustaining its healthy operating margins. These markets are typically difficult to access due to their fragmented nature and stringent regulatory requirements. The transaction is proposed to be funded largely through Lupin's existing cash reserves, given the company's strong liquidity position and healthy cash flow generation. As a result, this event is unlikely to have any adverse material impact on Lupin's credit profile. Nonetheless, the company's ability to successfully integrate the acquired business will be monitored.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their description, Liquidity position, Rating sensitivities and key financial indicators: [Click here](#)

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Pharmaceuticals Corporate Credit Rating Methodology
Parent/Group support	Not Applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has considered the consolidated financials of Lupin. As on June 30, 2025, the company had 33 subsidiaries and one joint venture company, which are enlisted in Annexure-II.

About the company

LLSL is a wholly owned subsidiary of Lupin which was incorporated in FY2024 to carve out Lupin's domestic trade generics business. LLSL has a pan-India footprint with an increasing focus on tier II and III cities. The company operates through a network of over 1,500 stockists and a field force of more than 400 personnel.

Lupin was founded in 1968 by Late Dr. Desh Bandhu Gupta, father of the current Managing Director, Mr. Nilesh Gupta, after Dr. Gupta bought the Lupin trademark from Charak Pharmaceuticals. Set up originally as a proprietary concern, Lupin was converted into a private limited company in 1972 and became a public limited company in 1992. In June 2001, Lupin Chemicals merged with Lupin Laboratories Limited, following which the merged entity was renamed Lupin Limited. The amalgamation was aimed at leveraging the strengths of the two companies.

Lupin is an integrated pharmaceutical company with presence across research, manufacturing and marketing of formulations and APIs. The company's business mix can be broadly divided into two segments, formulations (accounted for 95% of Lupin's consolidated revenues in FY2025) and APIs (accounted for 5% of Lupin's consolidated revenues in FY2025). In terms of geographical presence, Lupin derived 38% of its FY2025 revenue from the United States, 34% from India, 13% from developed markets (comprising Canada, Australia, Europe and others) and 11% from other emerging markets (comprising LATAM, South Africa, the Philippines and Rest of the world).

As per the company, it is the third largest pharmaceutical player in US by prescriptions and the eighth largest company in the Indian pharmaceutical market.

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Current				Chronology of rating history for the past 3 years					
	FY2026				FY2025		FY2024		FY2023	
	Type	Amount Rated (Rs. crore)	Date	Rating	Date	Rating	Date	Rating	Date	Rating
Fund based/Non fund-based limits	Short term	10.00	Oct 09, 2025	[ICRA]A1+	-	-	-	-	-	-

			Jun 30, 2025	[ICRA]A1+	-	-	-	-	-	-
Unallocated Limits	Short Term	15.00	Oct 09, 2025	[ICRA]A1+	-	-	-	-	-	-
			Jun 30, 2025	[ICRA]A1+	-	-	-	-	-	-

Complexity level of the rated instruments

Instrument	Complexity indicator
Short-term-fund-based/non-fund based facilities	Simple
Short-term – Unallocated Limits	Not Applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click here](#)

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook
NA	Short-term-fund-based/non-fund-based facilities	NA	NA	NA	10.00	[ICRA]A1+
NA	Unallocated Limits	NA	NA	NA	15.00	[ICRA]A1+

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company Name	Lupin Ownership	Consolidation Approach
Lupin Pharmaceuticals, Inc.	100.00%	Full Consolidation
Hormosan Pharma GmbH	100.00%	Full Consolidation
Pharma Dynamics (Proprietary) Limited	100.00%	Full Consolidation
Lupin Australia Pty Limited	100.00%	Full Consolidation
Nanomi B.V. (formerly known as Lupin Holding B.V.)	100.00%	Full Consolidation
Lupin Atlantis Holdings SA	100.00%	Full Consolidation
Multicare Pharmaceuticals Philippines Inc.	51.00%	Full Consolidation
Generic Health Pty Limited	100.00%	Full Consolidation
Lupin Healthcare (UK) Limited [formerly Lupin (Europe) Limited]	100.00%	Full Consolidation
Lupin Pharma Canada Limited	100.00%	Full Consolidation
Lupin Diagnostics Limited (formerly Lupin Healthcare Limited)	100.00%	Full Consolidation
Lupin Mexico S.A. de C.V.	100.00%	Full Consolidation
Lupin Philippines Inc.	100.00%	Full Consolidation
Generic Health SDN. BHD.	100.00%	Full Consolidation
Lupin Inc.	100.00%	Full Consolidation
Laboratorios Grin S.A. de C.V.	100.00%	Full Consolidation
Medquímica Indústria Farmacêutica LTDA	100.00%	Full Consolidation
Novel Laboratories	100.00%	Full Consolidation
Lupin Research Inc.	100.00%	Full Consolidation
Avenue Coral Springs LLC	100.00%	Full Consolidation
Lupin Europe GmbH	100.00%	Full Consolidation
Lupin Management Inc (Formerly Lupin IP Ventures Inc.)	100.00%	Full Consolidation
Lupin Biologics Limited (India)	100.00%	Full Consolidation
Lupin Oncology Inc. (USA)	100.00%	Full Consolidation
Lupin Digital Health Limited (India)	100.00%	Full Consolidation
Southern Cross Pharma Pty Ltd	100.00%	Full Consolidation
Lupin NZ Limited (with effect from August 8, 2024)	100.00%	Full Consolidation

Company Name	Lupin Ownership	Consolidation Approach
Lupin Lanka (Private) Ltd (with effect from August 05, 2024)	100.00%	Full Consolidation
Lupin Manufacturing Solutions Limited	100.00%	Full Consolidation
Lupinlife Consumer Healthcare Limited (with effect from March 08, 2025)	100.00%	Full Consolidation
Lupin Life Science Limited (formerly Lupin Atharv Ability Limited)	100.00%	Full Consolidation
Medisol S.A.S	100.00%	Full Consolidation
Renascence Pharma Limited (U.K.) (with effect from 2 April 2025)	100.00%	Full Consolidation
Joint Venture		
YL Biologics Limited	45.00%	Equity method

Source: Company results Q1FY2026 and annual report FY2025

ANALYST CONTACTS

Jitin Makkar

+91 124 4545 368

jitinm@icraindia.com

Kinjal Shah

+91 22 6114 3442

kinjal.shah@icraindia.com

Deepak Jotwani

+91 124 4545 870

deepak.jotwani@icraindia.com

Aruna Ganesh

+91 22 6114 3459

aruna.ganesh@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.